Figure 1. Allogeneic MSC/CCL19 retain in tumor longer than fibroblast (A) iMSC/CCL19 derived from C57BL/6 mice were subcutaneously co-injected with CT26 colon carcinoma into BALB/c mice. 8 and 12 days after co-injection, the survivability of iMSC/CCL19 was evaluated by genomic PCR with a primer set which detect the EGFP gene tagged in iMSC/CCL19. (B) iMSC/CCL19 derived from BALB/c mice were co-injected with B16-OVA into C57BL/6 mice. (C) C57BL/6 splenocytes were stimulated with mitomycin C-treated BALB/c splenocytes. After 4 days, iFib and iMSC which derived from C57BL/6 and BALB/c mice were co-cultured for 24 hours. Relative cell viability was shown. **p<0.01 by two-sided t-test. These experiments were performed twice. CCL19, (C-C motif) ligand 19; iMSC, immortalized mesenchymal stem cell.